Merck: to study drug combo to treat cervical cancer

(CercleFinance.com) - Singapore-based biotech firm Tessa said on Tuesday that it would collaborate with US industry heavyweight Merck to test a combination of drugs for the treatment of cervical cancer.


Under the agreement, Tessa will conduct a multi-center Phase 1b/2 trial to evaluate the safety and efficacy of the combination of Tessa's therapy TT12 and Merck's immunotherapy Keytruda in patients with recurrent or metastatic HPV 16 and 18-positive cervical cancer.

The trial is planned to be conducted in the United States, Singapore and South Korea, Tessa said.

Copyright (c) 2019 CercleFinance.com. All rights reserved.